REV1 and carcinoma of esophagus: The results suggested that the expression of REV1 was significantly elevated relative to normal controls in cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck cancer (HNSC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC) and stomach adenocarcinoma (STAD).